After delaying their decision by three months to review new information, the FDA has cleared Johnson & Johnson and Legend’s BCMA CAR-T rival cilta-cel, setting the stage for a showdown in multiple myeloma. 传奇生物car-t疗法获批，盘后上涨10%.$和铂医药-B(02142)$